GrayBug to Present at the 6th Annual Conference of the Arnold and Mabel Beckman Initiative for Macular Research


January 9, 2014 – GrayBug is pleased to announce that it has been invited to present at the 6th Annual conference of the Arnold and Mabel Beckman Initiative for Macular Research (BIMR) at the Beckman Center of the National Academies of Science and Engineering on January 23-25, 2014, in Irvine, CA.

About the BIMR

Through a generous grant from the Arnold and Mabel Beckman Foundation, the Beckman Initiative for Macular Research (BIMR) brings together outstanding scientists, engineers, medical researchers, and clinicians — all focused on a common goal: developing a better understanding of atrophic macular degeneration.

Related News

Press release

Graybug Vision Expands Executive Leadership Team with Key Hires

Redwood City, CA – December 11, 2017 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for vision-threatening diseases including wet (neovascular) age-related macular degeneration (AMD) and glaucoma, today announced Read more…

Press release

Graybug Vision to Participate in Upcoming Industry Conferences

Redwood City, CA – November 6, 2017 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for vision-threatening diseases including wet (neovascular) age-related macular degeneration (AMD) and glaucoma, today announced Read more…

Press release

Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet Age-related Macular Degeneration

– Novel Injectable Formulation for Potential Twice Per Year Treatment – Redwood City, CA – September 19, 2017 – Graybug Vision, Inc., a clinical-stage, venture-held pharmaceutical company committed to developing potentially transformative therapies for vision-threatening Read more…